Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-22T07:38:34.977Z Has data issue: false hasContentIssue false
  • English
  • Français

Compulsivity, impulsivity, and the DSM-5 process

Published online by Cambridge University Press:  07 November 2013

Gregory S. Berlin  and
Eric Hollander
Gregory S. Berlin
Affiliation:
Autism and Obsessive-Compulsive Spectrum Program, Albert Einstein College of Medicine & Montefiore Medical Center, Bronx, New York, USA
Eric Hollander*
Affiliation:
Autism and Obsessive-Compulsive Spectrum Program, Albert Einstein College of Medicine & Montefiore Medical Center, Bronx, New York, USA
*
*Address for correspondence: Eric Hollander, Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine & Montefiore Medical Center, 111 E. 210th Street, Bronx, NY 10467, USA. (Email: [email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Compulsivity and impulsivity are cross-cutting, dimensional symptom domains that span traditional diagnostic boundaries. We examine compulsivity and impulsivity from several perspectives and present implications for these symptom domains as they relate to classification. We describe compulsivity and impulsivity as general concepts, from the perspectives of the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) Research Planning Agenda, and from the DSM-5 workgroups, literature reviews, and field trials. Finally, we detail alternative modes of classification for compulsivity and impulsivity in line with the Research Domain Criteria (RDoC) and International Classification of Diseases (ICD-11).

Keywords

Compulsivitycross-cutting symptom domainsDSM-5impulsivityRDoC
Type
Review Articles
Information
CNS Spectrums , Volume 19 , Issue 1 , February 2014 , pp. 62 - 68
Copyright
Copyright © Cambridge University Press 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Robbins, T, Curran, H, de Wit, H. Special issue on impulsivity and compulsivity. Psychopharmacology (Berl). 2012; 219(2): 251–252.CrossRefGoogle ScholarPubMed
2. Meda, SA, Stevens, MC, Potenza, MN, etal. Investigating the behavioral and self-report constructs of impulsivity domains using principal component analysis. Behav Pharmacol. 2009; 20(5–6): 390–399.Google Scholar
3. Dalley, JW, Everitt, BJ, Robbins, TW. Impulsivity, compulsivity, and top-down cognitive control. Neuron. 2011; 69(4): 680–694.CrossRefGoogle ScholarPubMed
4. Robbins, TW, Gillan, CM, Smith, DG, de Wit, S, Ersche, KD. Neurocognitive endophenotypes of impulsivity and compulsivity: towards dimensional psychiatry. Trends Cogn Sci. 2012; 16(1): 81–91.Google Scholar
5. Fibbe, LA, Cath, DC, van den Heuvel, OA, etal. Relationship between movement disorders and obsessive-compulsive disorder: beyond the obsessive-compulsive-tic phenotype. A systematic review. J Neurol Neurosurg Psychiatry.. 2012; 83(6): 646–654.CrossRefGoogle ScholarPubMed
6. el-Guebaly, N, Mudry, T, Zohar, J, Tavares, H, Potenza, MN. Compulsive features in behavioural addictions: the case of pathological gambling. Addiction. 2012; 107(10): 1726–1734.Google Scholar
7. Kashyap, H, Fontenelle, LF, Miguel, EC, etal. “Impulsive compulsivity” in obsessive-compulsive disorder: a phenotypic marker of patients with poor clinical outcome. J Psychiatr Res. 2012; 46(9): 1146–1152.CrossRefGoogle ScholarPubMed
8. Hollander, E, Wong, CM. Obsessive-compulsive spectrum disorders. JClin Psychiatry. 1995; 56(Suppl 4): 3–6; discussion 53–55.Google Scholar
9. Hollander, E, Rosen, J. Impulsivity. J Psychopharmacol. 2000; 14(2 Suppl 1): S39–S44.Google Scholar
10. Hollander, E, Zohar, J, Sirovatka, PJ, Regier, DA. Obsessive-Compulsive Spectrum Disorders: Refining the Research Agenda for DSM-5. Arlington, VA: American Psychiatric Association; 2011.Google Scholar
11. Zohar, J. Obsessive-Compulsive Disorder: Current Science and Clinical Practice. West Sussex, UK: Wiley-Blackwell; 2012.Google Scholar
12. American Psychiatric Association. Research Planning Launch/Methods Conference. APA Website. 2013. Available at http://www.dsm5.org/Research/Pages/ResearchPlanningLaunchMethodsConference%28February18-20,2004%29.aspx. Accessed March 27, 2013.Google Scholar
13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 2000.Google Scholar
14. Potenza, MN. Review. The neurobiology of pathological gambling and drug addiction: an overview and new findings. Philos Trans R Soc Lond B Biol Sci. 2008; 363(1507): 3181–3189.CrossRefGoogle ScholarPubMed
15. Peles, E, Schreiber, S, Sutzman, A, Adelson, M. Attention deficit hyperactivity disorder and obsessive-compulsive disorder among former heroin addicts currently in methadone maintenance treatment. Psychopathology. 2012; 45(5): 327–333.Google Scholar
16. McElroy, SL, Soutullo, CA, Beckman, DA, Taylor, P Jr, Keck, PE Jr. DSM-IV intermittent explosive disorder: a report of 27 cases. J Clin Psychiatry. 1998; 59(4): 203–210; quiz 211.Google Scholar
17. Hollander, E, King, A, Delaney, K, Smith, CJ, Silverman, JM. Obsessive-compulsive behaviors in parents of multiplex autism families. Psychiatry Res. 2003; 117(1): 11–16.Google Scholar
18. Fineberg, NA, Potenza, MN, Chamberlain, SR, etal. Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative review. Neuropsychopharmacology. 2010; 35(3): 591–604.Google Scholar
19. Graybiel, AM. Network-level neuroplasticity in cortico-basal ganglia pathways. Parkinsonism Relat Disord. 2004; 10(5): 293–296.Google Scholar
20. Leonard, HL, Swedo, SE, Rapoport, JL, etal. Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents: a double-blind crossover comparison. Arch Gen Psychiatry. 1989; 46(12): 1088–1092.Google Scholar
21. Hollander, E, Allen, A, Kwon, J, etal. Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry. 1999; 56(11): 1033–1039.CrossRefGoogle ScholarPubMed
22. Huh, J, Goebert, D, Takeshita, J, Lu, BY, Kang, M. Treatment of generalized anxiety disorder: a comprehensive review of the literature for psychopharmacologic alternatives to newer antidepressants and benzodiazepines. Prim Care Companion CNS Disord. 2011; 13(2): PCC.08r00709.Google Scholar
23. Kalus, O, Asnis, GM, Rubinson, E, etal. Desipramine treatment in panic disorder. J Affect Disord. 1991; 21(4): 239–244.CrossRefGoogle ScholarPubMed
24. McDougle, CJ, Goodman, WK, Price, LH. The pharmacotherapy of obsessive-compulsive disorder. Pharmacopsychiatry. 1993; 26(Suppl 1): 24–29.Google Scholar
25. Kolevzon, A, Mathewson, KA, Hollander, E. Selective serotonin reuptake inhibitors in autism: a review of efficacy and tolerability. J Clin Psychiatry. 2006; 67(3): 407–414.Google Scholar
26. Hollander, E, Phillips, A, Chaplin, W, etal. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology. 2005; 30(3): 582–589.CrossRefGoogle ScholarPubMed
27. Hollander, E, Soorya, L, Chaplin, W, etal. A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. Am J Psychiatry. 2012; 169(3): 292–299.CrossRefGoogle ScholarPubMed
28. American Psychiatric Association. DSM-5 development: DSM-5 timeline. 2012. Available at: http://www.dsm5.org/about/Pages/Timeline.aspx. Accessed March 27, 2013.Google Scholar
29. American Psychiatric Association. DSM-5 development: Why is the DSM being revised? 2013. Available at: http://www.dsm5.org/about/Pages/faq.aspx. Accessed March 24, 2013.Google Scholar
30. Wittchen, HU, Gloster, AT, Beesdo-Baum, K, Fava, GA, Craske, MG. Agoraphobia: a review of the diagnostic classificatory position and criteria. Depress Anxiety. 2010; 27(2): 113–133.Google Scholar
31. Phillips, KA, Stein, DJ, Rauch, SL, etal. Should an obsessive-compulsive spectrum grouping of disorders be included in DSM-5? Depress Anxiety. 2010; 27(6): 528–555.Google Scholar
32. American Psychiatric Association. DSM-5 development: Appendix B: Protocol for DSM-5 field trials in academic/large clinic settings [serial online]. 2010. Available at: http://www.dsm5.org/Documents/Revised%20Field%20Trial%20Protocol%20for%20Large%20Clinical%20Settings_042910_II.pdf. Accessed March 24, 2013.Google Scholar
33. Clarke, DE, Narrow, WE, Regier, DA, etal. DSM-5 field trials in the United States and Canada, part I: study design, sampling strategy, implementation, and analytic approaches. Am J Psychiatry. 2013; 170(1): 43–58.CrossRefGoogle ScholarPubMed
34. Krueger, RF, Derringer, J, Markon, KE, Watson, D, Skodol, AE. Initial construction of a maladaptive personality trait model and inventory for DSM-5. Psychol Med. 2012; 42(9): 1879–1890.Google Scholar
35. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Arlington, VA: American Psychiatric Association; 2013.Google Scholar
36. American Psychiatric Association. DSM-5 development: obsessive compulsive disorders fact sheet. Available at: http://www.dsm5.org/Documents/Obsessive%20Compulsive%20Disorders%20Fact%20Sheet.pdf. Accessed July 27, 2013.Google Scholar
37. American Psychiatric Association. DSM-5 development: DSM-5 draft criteria draws nearly 2,300 responses. 2013. Available at: http://www.dsm5.org/Documents/12-30%20Final%20DSM%20Public%20Comment.pdf. Accessed April 25, 2013.Google Scholar
38. National Institute of Mental Health. Research domain criteria. NIMH Web site. 2013. Available at: http://www.nimh.nih.gov/research-funding/rdoc/index.shtml. Accessed April 7, 2013.Google Scholar
39. Cuthbert, BN, Insel, TR. Toward the future of psychiatric diagnosis: the seven pillars of RDoC. BMC Med. 2013; 11: 126.Google Scholar
40. Morris, SE, Cuthbert, BN. Research Domain Criteria: cognitive systems, neural circuits, and dimensions of behavior. Dialogues Clin Neurosci. 2012; 14(1): 29–37.Google Scholar
41. Organization, WH. Classifications: International Classification of Diseases. WHO Web site. 2013. Available at: http://www.who.int/classifications/icd/en/. Accessed March 27, 2013.Google Scholar